MedTrace Logo

Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.

NCT00933517 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2014-03-21

No results posted yet for this study

Summary

The purpose of this study is to assess the pathological response rate in operable breast cancer patients treated by neoadjuvant combination: "FEC-Taxotere/Vectibix".

Conditions

  • Pathological Response Rate

Interventions

DRUG

vectibix

9mg/kg at D1 of each 21-days cycle

DRUG

fluorouracile

500 mg/m2 at D1 of each 21-days cycle

DRUG

Epirubicine

100 mg/m2 at D1 of each 21-days cycle

DRUG

cyclophosphamide

500 mg/m2 at D1 of each 21 dyas cycle

DRUG

docetaxel

100 mg/m2 at D1 of each 21 days cycle

Sponsors & Collaborators

  • Centre Jean Perrin

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00933517 on ClinicalTrials.gov